ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Edwards Lifesciences (EW) Reports Q4: Everything You Need To Know Ahead Of Earnings

EW Cover Image

Medical technology company Edwards Lifesciences (NYSE: EW) will be reporting results tomorrow after market close. Here’s what to look for.

Edwards Lifesciences missed analysts’ revenue expectations by 13.1% last quarter, reporting revenues of $1.35 billion, down 8.5% year on year. It was a strong quarter for the company, with an impressive beat of analysts’ EPS estimates and a solid beat of analysts’ EPS guidance for next quarter estimates.

Is Edwards Lifesciences a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting Edwards Lifesciences’s revenue to grow 7.4% year on year to $1.36 billion, a reversal from the 6.1% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.55 per share.

Edwards Lifesciences Total Revenue

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Edwards Lifesciences has missed Wall Street’s revenue estimates six times over the last two years.

Looking at Edwards Lifesciences’s peers in the healthcare equipment and supplies segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Intuitive Surgical delivered year-on-year revenue growth of 25.2%, beating analysts’ expectations by 6.5%, and Envista reported revenues up 1.1%, topping estimates by 0.8%. Intuitive Surgical traded down 4% following the results while Envista was up 5.8%.

Read our full analysis of Intuitive Surgical’s results here and Envista’s results here.

Investors in the healthcare equipment and supplies segment have had steady hands going into earnings, with share prices flat over the last month. Edwards Lifesciences’s stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $79.49 (compared to the current share price of $70).

Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.

Recent Quotes

View More
Symbol Price Change (%)
AMZN  234.73
+0.85 (0.36%)
AAPL  285.43
+2.33 (0.82%)
AMD  216.82
-2.94 (-1.34%)
BAC  53.17
-0.07 (-0.12%)
GOOG  314.30
-0.82 (-0.26%)
META  639.41
-1.46 (-0.23%)
MSFT  489.79
+3.05 (0.63%)
NVDA  180.38
+0.46 (0.26%)
ORCL  202.57
+1.63 (0.81%)
TSLA  423.66
-6.48 (-1.51%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.